Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Obseva SA    OBSV   CH0346177709

OBSEVA SA (OBSV)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
16.89(c) 17.48(c) 18.13(c) 18.18(c) 18.15 Last
224 063 167 248 295 201 159 219 113 964 Volume
+2.43% +3.49% +3.72% +0.28% -0.17% Change
More quotes
Financials (USD)
Sales 2018 0,01 M
EBIT 2018 -79,6 M
Net income 2018 -78,4 M
Finance 2018 119 M
Yield 2018 -
Sales 2019 0,01 M
EBIT 2019 -102 M
Net income 2019 -101 M
Finance 2019 146 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 104 507x
EV / Sales2019 85 385x
Capitalization 778 M
More Financials
Company
ObsEva SA engages in the development of therapeutic treatments for woman's reproductive health and pregnancy.It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth.The company was founded by Ernest Loumaye and André Chollet in November 2012 and is... 
More about the company
Surperformance© ratings of Obseva SA
Trading Rating : Investor Rating :
More Ratings
Latest news on OBSEVA SA
08/08OBSEVA SA : to Host Earnings Call
AC
07/25ObsEva Expands Executive Team Hiring a Chief Commercial Officer
GL
07/13ObsEva SA to start trading today on the SIX Swiss Exchange
GL
06/15ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS ..
GL
02/28OBSEVA SA : Wired News – ObsEva Released Positive Top-line Results from IMPLANT2..
AC
02/23ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 p..
GL
2017ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm La..
GL
2017ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with..
GL
2017ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Ca..
GL
2017OBSEVA : Starts Phase 3 Clinical Program for Nolasiban in ART
PU
More news
Sector news : Bio Therapeutic Drugs
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/19SmartInsider - 1 director sold: A director at ObsEva SA sold 1,500 shares at .. 
09/17Obseva $OBSV Now Covered by JPMorgan Chase & Co.  
09/17Obseva $OBSV Now Covered by JPMorgan Chase & Co.  
09/17Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/17/2018)
1
09/17SOCIAL ACTIVITY: $OBSV - OBSEVA SA COMMON SHARES ? TradeIdeas via ?  
More tweets
Qtime:10
News from SeekingAlpha
09/17ObsEva up 13% 
09/17HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (09/17/2018) 
09/13Premarket analyst action - healthcare 
08/11Obseva SA (OBSV) CEO Ernest Loumaye on Q2 2018 Results - Earnings Call Transc.. 
08/08ObsEva beats by $0.04 
Chart OBSEVA SA
Duration : Period :
Obseva SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OBSEVA SA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 30,8 $
Spread / Average Target 69%
EPS Revisions
Managers
NameTitle
Ernest Loumaye Chief Executive Officer & Director
Frank A. G. M. Verwiel Chairman
Timothy M. Adams Chief Financial Officer
Jean-Pierre Gotteland Chief Scientific Officer
Elke Bestel Chief Medical Officer & Head-Pharmacovigilance
Sector and Competitors
1st jan.Capitalization (M$)
OBSEVA SA86.27%776
GILEAD SCIENCES5.40%97 887
VERTEX PHARMACEUTICALS20.17%46 021
REGENERON PHARMACEUTICALS3.81%41 426
NEUROCRINE BIOSCIENCES, INC.54.17%10 822
GENMAB2.04%10 170